{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-266027","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-06-10T21:04:43+00:00","discovered_at":"2026-06-10T21:06:00.271795+00:00","generated_at":"2026-06-10T21:06:47.527309+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Syndax issues $250M of 2.25% convertible notes due 2031, net proceeds ~$243M","bullets":["Issued $250M aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in private placement.","Net proceeds of approximately $243M after placement agent fees and expenses.","Proceeds to be used for general corporate purposes including R&D, commercialization, and business development.","Initial maximum conversion of 13,631,400 shares of common stock (conversion rate 54.5256 shares per $1,000).","Notes and conversion shares unregistered; issued under Section 4(a)(2) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-266027","json":"https://secwatch.observer/filing/0001193125-26-266027.json","markdown":"https://secwatch.observer/filing/0001193125-26-266027.md","text":"https://secwatch.observer/filing/0001193125-26-266027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/0001193125-26-266027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/d105044d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:06:47.527309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f47b87b03bc72351ed26ba68e77adf917ca4eb2","claim":"Syndax Pharmaceuticals Inc incurred convertible notes of $250.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 2.25% maturing due 2031.","evidence_excerpt":"issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/0001193125-26-266027-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$250.0 million aggregate principal amount"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Rate","value":"2.25%"},{"label":"Maturity","value":"due 2031"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"e73822ac53ac66ae3f170b3aad57339013f646f2","claim":"Syndax Pharmaceuticals Inc issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 of convertible note to certain investors for approximately $243.0 million net proceeds.","evidence_excerpt":"(and the foregoing description is qualified in its entirety by reference to such documents). Proceeds The Company’s net proceeds from the Private Placement were approximately $243.0 million, after deducting the placement agent’s fees and Private Placement expenses payable by the Company. The Company expects to use the net proceeds from the Private Placement for","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526266027/0001193125-26-266027-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Shares","value":"$250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031"},{"label":"Purchaser","value":"certain investors"},{"label":"Consideration","value":"approximately $243.0 million net proceeds"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}